Literature DB >> 11516940

In vitro antifungal activity of posaconazole against various pathogenic fungi.

K Uchida1, N Yokota, H Yamaguchi.   

Abstract

The antifungal activity of posaconazole (SCH56592), a new triazole antifungal, against stock cultures and fresh clinical isolates of a wide range of pathogenic fungi was compared with that of itraconazole, fluconazole and amphotericin B. Posaconazole inhibited growth of all the fungal species tested except Fusarium spp. at 1 mg/l or lower concentrations, showing a broad-spectrum antifungal activity. The activities of posaconazole for all the fungal species far surpassed those of fluconazole and were even superior to those of itraconazole for Aspergillus spp. as well as for many other fungal species.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11516940     DOI： 10.1016/s0924-8579(01)00363-6

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN： 0924-8579            Impact factor:   5.283


  11 in total

1.  Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations.

Authors:  Farkad Ezzet; David Wexler; Rachel Courtney; Gopal Krishna; Josephine Lim; Mark Laughlin
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Efficacy of posaconazole in a murine model of central nervous system aspergillosis.

Authors:  Jackie K Imai; Gaurav Singh; Karl V Clemons; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

3.  Activity of posaconazole in treatment of experimental disseminated zygomycosis.

Authors:  Eric Dannaoui; Jacques F G M Meis; David Loebenberg; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

Review 4.  Newer systemic antifungal agents : pharmacokinetics, safety and efficacy.

Authors:  Helen W Boucher; Andreas H Groll; Christine C Chiou; Thomas J Walsh
Journal:  Drugs       Date:  2004       Impact factor: 9.546

5.  Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.

Authors:  Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Emilia Mellado; Maria J Buitrago; Araceli Monzon; Juan Luis Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

6.  Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase.

Authors:  Paul A Mann; Raulo M Parmegiani; Shui-Qing Wei; Cara A Mendrick; Xin Li; David Loebenberg; Beth DiDomenico; Roberta S Hare; Scott S Walker; Paul M McNicholas
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

7.  Ocular and systemic posaconazole(SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis.

Authors:  W E Sponsel; J R Graybill; H L Nevarez; D Dang
Journal:  Br J Ophthalmol       Date:  2002-07       Impact factor: 4.638

Review 8.  The use of antifungal therapy in neonatal intensive care.

Authors:  Daniela Testoni; P Brian Smith; Daniel K Benjamin
Journal:  Clin Perinatol       Date:  2012-01-11       Impact factor: 2.642

9.  Acute Cardiac Failure due to Intra-Atrial Mass Caused by Zygomycetes in an Immunocompromised Paediatric Patient.

Authors:  G J van de Glind; C E M Gidding; C M W Verlaat; K Duthoi; A P C Backx; P E Verweij; A Warris
Journal:  Case Rep Med       Date:  2010-07-04

10.  An Investigation on in vitro and in vivo Antimicrobial Properties of the Antidepressant: Amitriptyline Hydrochloride.

Authors:  Anurup Mandal; Chandrima Sinha; Aditya Kumar Jena; Soma Ghosh; Amalesh Samanta
Journal:  Braz J Microbiol       Date:  2010-09-01       Impact factor: 2.476
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.